Citadel Advisors
BHVN

Citadel Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Citadel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-185,618
Closed -$28.1M – 16125
2022
Q3 		$28.1M Sell
185,618
-51,157
-22% -$7.58M 0.01% 1546
2022
Q2 		$34.5M Buy
236,775
+90,863
+62% +$11.6M 0.01% 1342
2022
Q1 		$17.3M Buy
145,912
+105,146
+258% +$13.1M ﹤0.01% 2157
2021
Q4 		$5.62M Sell
40,766
-122,215
-75% -$15.5M ﹤0.01% 4094
2021
Q3 		$22.6M Buy
162,981
+128,607
+374% +$16.1M ﹤0.01% 1860
2021
Q2 		$3.34M Sell
34,374
-9,548
-22% -$775K ﹤0.01% 5347
2021
Q1 		$3M Sell
43,922
-81,517
-65% -$6.59M ﹤0.01% 5450
2020
Q4 		$10.8M Buy
125,439
+75,892
+153% +$6.43M ﹤0.01% 2557
2020
Q3 		$3.22M Sell
49,547
-248,772
-83% -$16.3M ﹤0.01% 3867
2020
Q2 		$21.8M Buy
298,319
+83,694
+39% +$4.45M 0.01% 1436
2020
Q1 		$7.3M Sell
214,625
-73,472
-26% -$3.36M ﹤0.01% 2234
2019
Q4 		$15.7M Sell
288,097
-670,968
-70% -$33.2M 0.01% 1718
2019
Q3 		$40M Sell
959,065
-333,437
-26% -$14.1M 0.02% 910
2019
Q2 		$56.6M Buy
1,292,502
+593,727
+85% +$33.5M 0.03% 661
2019
Q1 		$36M Sell
698,775
-239,464
-26% -$10.3M 0.02% 882
2018
Q4 		$34.7M Sell
938,239
-42,508
-4% -$1.53M 0.02% 828
2018
Q3 		$36.8M Buy
980,747
+129,697
+15% +$4.77M 0.02% 941
2018
Q2 		$33.6M Buy
851,050
+411,017
+93% +$13M 0.02% 921
2018
Q1 		$11.3M Buy
440,033
+179,024
+69% +$5.35M 0.01% 1596
2017
Q4 		$7.04M Buy
261,009
+57,307
+28% +$1.58M ﹤0.01% 2089
2017
Q3 		$7.61M Buy
+203,702
New +$6.18M 0.01% 1871

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Citadel Advisors's BHVN Position: Q4 2022 in Review

Citadel Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 185,618 shares — an estimated $28.1M sold.

Citadel Advisors first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $56.6M in Q2 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Citadel Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 185,618 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $28.1M.
  • Citadel Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • Citadel Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $56.6M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.